|Videos|March 29, 2021

Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.


Latest CME